DEY : Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and ...

May 20, 2008 – Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that concomitant therapy with Perforomist™ Inhalation Solution (formoterol fumarate inhalation solution; FFIS), delivered by nebulization, and Spiriva^® (tiotropium; TIO) is significantly more effective than treatment with tiotropium alone.
Perforomist Inhalation Solution was approved in 2008 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is the only FDA-approved nebulized formoterol fumarate... Dey's Press Release -

DEY, Clinical Trials for Perforomist™ Inhalation Solution to be Presented at CHEST 2007

October 16, 2007 - Dey, L.P. , a subsidiary of Mylan Inc. (NYSE: MYL), announces three clinical data presentations will be given at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP) on Wednesday, October 24, 2007 at the McCormick Place Convention Center in Chicago. Data will be presented from two safety studies that were included as part of the New Drug Application (NDA) filing to the U.S. Food and Drug Administration (FDA) for Perforomist™ Inhalation Solution. The third presents results from a Phase IIIb study of the concomitant use of Perforomist™ Inhalation Solution with tiotropium for the treatment of COPD... Dey's Press Release-